Molecular Genetics of Fanconi Anaemia


Cells derived from Fanconi anaemia (FA) patients display hypersensitivity to deoxyribonucleic acid (DNA) cross‐linking agents such as MMC and DEB. Treatment with these agents induces an abnormally prolonged cell cycle arrest in S phase and an accumulation of cells with 4N DNA. Based on this response, the FA pathway has been hypothesised to function in sensing DNA damage induced by these agents and in initiating its repair. This hypothesis has been supported by work elucidating the interactions of FA proteins with proteins known to be involved in DNA‐damage sensing, signalling and repair. Additionally, a significant body of work has pointed to a role of the FA pathway in the cellular response to oxidative stress. Although the exact mechanisms and functions of the FA pathway are yet to be discovered, the interaction of the members of the FA pathway with proteins associated with DNA repair, cellular signalling and oxidative stress management leads to the hypothesis that the FA pathway proteins serve many varied functions throughout the cell.

Key Concepts:

  • The FA pathway overlaps significantly with other DNA repair pathways such as homologous recombination, translesion synthesis and mismatch repair.

  • FA pathway proteins are involved in the intricate cellular signalling that occurs following DNA damage.

  • FA pathway proteins are involved in regulating oxidative stress.

  • FA mutant cells display hypersensitivity to DNA damage, particularly DNA crosslink's.

  • FA patients are particularly prone to malignancy, especially myeloid leukemia and squamous cell carcinomas of the head and neck and genitourinary track.

Keywords: Fanconi anaemia; DNA damage; DNA repair; cancer susceptibility; DNA damage hypersensitivity

Figure 1.

The FA pathway proteins: The FA pathway is composed of at least 13 genes. Each of these genes, when biallelically mutated, causes FA. The encoded proteins can be subdivided within the FA pathway into three groups: proteins that make up the core complex, the FANCD2 and FANCI proteins which compose the ID complex and five downstream effector proteins: FANCD1/BRCA2, FANCJ/BRIP1/BACH1, FANCN/PALB2, FANCO/RAD51C and FANCP/SLX4. Following treatment with DNA crosslinking agents or during S phase of the cell cycle, FANCD2 and FANCI become monoubiquitylated. An intact core complex is required for these modifications, which result in the relocation of the two proteins to chromatin within cells. Within chromatin, FANCD2 and FANCI colocalise with DNA repair proteins including the downstream effector, FA proteins, at sites of DNA damage in nuclear foci. FA proteins are in blue.

Figure 2.

Homologous recombination: In response to the forms of DNA damage such as DSBs, the mammalian histone, H2A variant H2AX, is incorporated into DNA at sites surrounding the damage and is phosphorylated at serine 139 to generate γH2AX (a). The γH2AX histone variant serves as a marker of DSBs and helps to initiate the accumulation of DNA‐damage sensing and repairing proteins such as NBS1 and BRCA1 to these sites of damage (b). These damage sensing proteins recruit nucleases which resects the DNA surrounding the damage in order to produce 3′ overhangs, which are necessary for the next step of strand invasion. BRCA2 nucleates RAD51 onto the 3′ DNA overhangs in order to stabilise the ssDNA and to promote its invasion of its complementary duplex (c). Strand invasion results in D‐loop structure formation and subsequent DNA synthesis using the complementary strand as a template (d). The D‐loop structure is resolved by either (SDSA) or (DSBR). In the SDSA pathway, the D loop is unwound and the ssDNA strand anneals with its complementary ssDNA on the other side of the DSB. Gap‐filling DNA synthesis and ligation ensue, resulting in noncrossover products (e). In the DSBR pathway, the second end of the DSB is captured to form an intermediate structure containing two (HJ) which are extended by gap filling DNA synthesis and ligation. Resolution of the HJ can result in either crossover or noncrossover products. The BLM helicase promotes noncrossover product formation and resolution of Holliday junction structures (f, g). FA proteins interact with several of the proteins involved in HR including H2AX, BRCA1, RAD51 and BLM.

Figure 3.

Translesion synthesis: To continue replicating through sites of DNA damage which block replicative polymerases and lead to replication fork stalling, (a) cells employ the use of TLS polymerases. Upon encountering DNA damage, RAD6 and RAD18 ubiquitylate PCNA, decreasing its affinity for replicative polymerases and increasing its affinity for TLS polymerases that contain an ubiquitin‐binding motif (b). This increase in affinity results in polymerase switching and replicating through sites of DNA damage using the appropriate TLS polymerase. After the replication machinery has passed the site of damage, the TLS polymerase falls off DNA, PCNA gets deubiquitylated by USP1 and replicative polymerases are able to once again interact with PCNA and resume normal replication (c). FA proteins interact with several of the proteins involved in TLS, including PCNA, the TLS polymerase REV1 and USP1.



Bleuyard J, Buisson R, Masson J et al. (2012) ChAM, a novel motif that mediates PALB2 intrinsic chromatin binding and facilitates DNA repair. EMBO Reports 13: 135–141.

Cantor SB and Xie J (2010) Assessing the link between BACH1/FANCJ and MLH1 in DNA crosslink repair. Environmental and Molecular Mutagenesis 51(6): 500–507.

Collins NB, Wilson JB, Bush T et al. (2009) ATR‐dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. Blood 113: 2181–2190.

Collis SJ, Ciccia A, Deans AJ et al. (2008) FANCM and FAAP24 function in ATR mediated checkpoint signaling independently of the Fanconi anemia core complex. Molecular Cell 32: 313–324.

Crossan GP and Patel KJ (2012) The Fanconi anaemia pathway orchestrates incisions at sites of crosslinked DNA. Journal of Pathology 226(2): 326–337.

Cybulski KE and Howlett NG (2011) FANCP/SLX4: A Swiss army knife of DNA interstrand crosslink repair. Cell Cycle 10(11): 1757–1763.

Dray E, Etchin J, Wiese C et al. (2010) Enhancement of RAD51 recombinase activity by the tumor suppressor PALB2. Nature Structural and Molecular Biology 17(10): 1255–1260.

Fagerlie S, Lensch MW, Pang Q et al. (2001) The Fanconi anemia group C gene product: signaling functions in hematopoietic cells. Experimental Hematology 29: 1371–1381.

Folias A, Matkovic M, Bruun D et al. (2002) BRCA1 interacts directly with the Fanconi anemia protein FANCA. Human Molecular Genetics 11(21): 2591–2597.

Gari K, Decaillet C, Stasiak AZ et al. (2008) The Fanconi anemia protein FANCM can promote branch migration of holliday junctions and replication forks. Molecular Cell 29(1): 141–148.

Garner E and Smogorzewska A (2011) Ubiquitylation and the Fanconi anemia pathway. FEBS Letters 18: 2853–2860.

van der Heijden MS, Yeo CJ, Hruban RH et al. (2003) Fanconi anemia gene mutations in young‐onset pancreatic cancer. Cancer Research 63: 2585–2588.

Hinz JM (2010) Role of homologous recombination in DNA interstrand crosslink repair. Environmental and Molecular Mutagenesis 51(6): 582–603.

Hussain S, Wilson JB, Medhurst AL et al. (2004) Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways. Human Molecular Genetics 13(12): 1241–1248.

Hussain S, Witt E, Huber PAJ et al. (2003) Direct interaction of the Fanconi anemia protein FANCG with BRCA2/FANCD1. Human Molecular Genetics 12(19): 2503–2510.

Kim H and D'Andrea AD (2012) Regulation of DNA cross‐link repair by the Fanconi anemia/BRCA pathway. Genes and Development 26: 1393–1408.

Kim H, Yang K, Dejsuphong D et al. (2012) Regulation of REV1 by the Fanconi anemia core complex. Nature Structural and Molecular Biology 19(2): 164–170.

Kim JM, Kee Y, Gurtan A et al. (2008) Cell cycle dependent chromatin loading of the Fanconi anemia core complex by FANCM/FAAP24. Blood 111(10): 5215–5222.

Li J, Zou C, Bai Y et al. (2006) DSS1 is required for the stability of BRCA2. Oncogene 25(8): 1186–1194.

Marsit CJ, Liu M, Nelson HH et al. (2004) Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23: 1000–1004.

Medhurst AL, El Houari L, Steltenpool J et al. (2006) Evidence for subcomplexes in the Fanconi anemia pathway. Blood 108(6): 2072–2080.

Meetei AR, de Winter JP, Medhurst AL et al. (2003a) A novel ubiquitin ligase is deficient in Fanconi anemia. Nature Genetics 35(2): 165–170.

Meetei AR, Sechi S, Wallisch M et al. (2003b) A multiprotein nuclear complex connects Fanconi anemia and Bloom syndrome. Molecular and Cellular Biology 23(10): 3417–3426.

Narayan G, Arias‐Pulido H, Nandula SV et al. (2004) Promoter hypermethylation of FANCF: disruption of Fanconi anemia‐BRCA pathway in cervical cancer. Cancer Research 64: 2994–2997.

Nijman SM, Huang TT, Dirac AM et al. (2005) The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Molecular Cell 17(3): 331–339.

Nojima K, Hochegger H, Saberi A et al. (2005) Multiple repair pathways mediate tolerance to chemotherapeutic cross‐linking agents in vertebrate cells. Cancer Research 65(24): 11704–11711.

Pace P, Johnson M, Tan WM et al. (2002) FANCE: the link between Fanconi anemia complex assembly and activity. EMBO Journal 21(13): 3414–3423.

Pagano G, Talamanca AA, Castello G et al. (2012) Oxidative stress in Fanconi anemia: from cells and molecules towards prospects in clinical management. Biological Chemistry 393: 11–21.

Sarkies P, Murat P, Phillips LG et al. (2011) FANCJ coordinates two pathways that maintain epigenetic stability at G quadruplex DNA. Nucleic Acids Research 10: 1–14.

Somyajit K, Subramanya S and Nagaraju G (2012) Distinct roles of FANCO/RAD51C protein in DNA damage signaling and repair: implications for Fanconi anemia and breast cancer susceptibility. Journal of Biological Chemistry 287: 3366–3380.

Taniguchi T and D'Andrea AD (2006) Molecular pathogenesis of Fanconi anemia: recent progress. Blood 107(11): 4223–4233.

Taniguchi T, Tischkowitz M, Ameziane N et al. (2003) Disruption of the Fanconi anemia – BRCA pathway in cisplatin‐sensitive ovarian tumors. Nature Medicine 9: 568–574.

Thompson LH, Hinz JM, Yamada NA et al. (2005) How Fanconi anemia proteins promote the four R's: replication, recombination, repair, and recovery. Environmental and Molecular Mutagenesis 45(2‐3): 128–142.

Tischkowitz M, Ameziane N, Qaisfisz Q et al. (2003) Biallelic silencing of the Fanconi anemia gene FANCF in acute myeloid leukemia. British Journal of Hematology 123: 469–471.

Williams SA, Longerich S, Sung P et al. (2011a) The E3 ubiquitin ligase RAD18 regulates ubiquitylation and chromatin loading of FANCD2 and FANCI. Blood 117: 5078–5087.

Williams SA, Wilson JB, Clark AP et al. (2011b) Functional and physical interaction between the mismatch repair and FA‐BRCA pathways. Human Molecular Genetics 20(22): 4395–4410.

Wilson JB, Yamamoto K, Marriott AS et al. (2008) FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3. Oncogene 27: 3641–3652.

de Winter JP and Joenje H (2009) The genetic and molecular basis of Fanconi anemia. Mutation Research 668: 11–19.

Xie Y, de Winter JP, Waisfisz Q et al. (2000) Aberrant Fanconi anemia protein profiles in acute myeloid leukemia cells. British Journal of Hematology 111: 1057–1064.

Yang H, Jeffrey PD, Miller J et al. (2002) BRCA2 function in DNA binding and recombination from a BRCA2‐DSS1‐ssDNA structure. Science 297(5588): 1837–1848.

Yu X, Chini CCS, He M et al. (2003) The BRCT domain is a phospho‐protein binding domain. Science 302(5645): 639–642.

Zanier R, Briot D, Villard JA et al. (2004) Fanconi anemia C gene product regulates the expression of genes involved in differentiation and inflammation. Oncogene 23: 5004–5013.

Zhang W, Zhou X, Zhao L et al. (2011) UBE2W interacts with FANCL and regulates the monoubiquitylation of Fanconi anemia protein FANCD2. Molecular Cell 31(2): 113–122.

Zhi G, Wilson J, Chen X et al. (2009) Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for Fanconi anemia pathway function and BRCA2 interaction. Cancer Research 69(22): 8775–8783.

Further Reading

Deans AJ and West SC (2011) DNA interstrand crosslink repair and cancer. Nature Reviews Cancer 11(7): 467–480.

Sengerova B, Wang AT and McHugh PJ (2011) Orchestrating the nucleases involved in DNA interstrand cross‐link (ICL) repair. Cell Cycle 10(23): 3999–4008.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Green, Allison M, and Kupfer, Gary M(Dec 2012) Molecular Genetics of Fanconi Anaemia. In: eLS. John Wiley & Sons Ltd, Chichester. [doi: 10.1002/9780470015902.a0024322]